Ramanan Athimalaipet V, Schneider Rayfel
Division of Pediatric Rheumatology, Hospital for Sick Children and Department of Pediatrics, University of Toronto, Ontario, Canada.
J Rheumatol. 2003 Feb;30(2):401-3.
Systemic onset juvenile rheumatoid arthritis (JRA) accounts for 10-15% of all JRA. Macrophage activation syndrome (MAS), which can also be considered as secondary hemophagocytic lymphohistiocytosis, is a potentially life-threatening complication of systemic onset JRA. We describe a child with systemic onset JRA who developed MAS after initiation of etanercept therapy.
全身型幼年类风湿关节炎（JRA）占所有JRA的10% - 15%。巨噬细胞活化综合征（MAS），也可被视为继发性噬血细胞性淋巴组织细胞增生症，是全身型JRA的一种潜在危及生命的并发症。我们描述了一名全身型JRA患儿，在开始使用依那西普治疗后发生了MAS。
